Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis
Authors:
- Simon Yu TianSTSimon Yu Tian
- Brian M. FeldmanBFBrian M. Feldman
- Joseph BeyeneJBJoseph Beyene
- Patrick E. BrownPBPatrick E. Brown
- Elizabeth M. UlerykEUElizabeth M. Uleryk
- Earl D. SilvermanESEarl D. Silverman
- 15 June 2015
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (8) , 1392-1400
Abstract
Objective.: To determine the most effective immunosuppressive therapy for the longterm management of proliferative lupus nephritis (PLN) based on the outcome of renal failure.Methods.: A systematic review of randomized controlled trials (RCT) was conducted. MEDLINE and EMBASE were searched. RCT designed to examine the maintenance treatment effectiveness of immunosuppressive agents for PLN were included. A Bayesian network metaanalysis of 2-arm and 3-arm trials was used. A skeptical prior assumption was used in sensitivity analysis. Four immunosuppressive agents were evaluated: cyclophosphamide (CYC), azathioprine (AZA), mycophenolate mofetil (MMF), and prednisone alone. The outcome of interest was renal failure during the study period, defined by serum creatinine (sCr) > 256µmol/l, doubling of sCr from baseline, and/or endstage renal disease.Results.: The OR (95% credible interval) of developing renal failure at 2–3 years was 0.72 (0.11, 4.49) for AZA versus CYC, 0.32 (0.04, 2.25) for MMF versus CYC, 2.40 (0.22, 36.94) for prednisone alone versus CYC, and 0.45 (0.11, 1.48) for MMF versus AZA. The probability (95% credible interval) of developing renal failure at 2 years as expected for each agent was 6% (0.7%, 24%) for MMF, 12% (2%, 37%) for AZA, 16% (5%, 33%) for CYC, and 31% (5%, 81%) for prednisone alone. After applying a skeptical prior in the Bayesian analysis, there was no evidence of benefit for 1 therapy over another.Conclusion.: Although the data suggest that MMF may be superior to other treatments for the maintenance treatment of PLN, the evidence is not conclusive.Keywords
This publication has 32 references indexed in Scilit:
- Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical TrialsArthritis & Rheumatism, 2013
- Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisAnnals of the Rheumatic Diseases, 2012
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- Therapy of lupus nephritis: lessons learned from clinical research and daily care of patientsArthritis Research & Therapy, 2012
- Indirect and mixed treatment comparisons in arthritis researchRheumatology, 2011
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialAnnals of the Rheumatic Diseases, 2010
- Prevalence and burden of pediatric-onset systemic lupus erythematosusNature Reviews Rheumatology, 2010
- Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcomeRheumatology, 2008
- Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamideKidney International, 2000
- Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprineArthritis & Rheumatism, 1974